While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers; APST Research data includes thousands of people liv ...
Medpage Today on MSN7d
Two Investigational Treatments for ALS Show Glimmer of HopeThe first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
GlobalData on MSN6d
Four regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
All four trials, part of the Massachusetts General Hospital’s HEALEY ALS platform trial (NCT05136885), failed to show an impact on ALS disease progression. The platform trial is examining ...
News Medical on MSN7d
ALS Drug-Testing Platform Speeds Therapeutic BreakthroughsAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback